Study of IBI363 for advanced small cell lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called IBI363 for people with extensive-stage small cell lung cancer whose cancer has continued to grow after immunotherapy and other treatments. It aims to see if IBI363 can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have extensive-stage small cell lung cancer (SCLC) that has spread beyond one lung.
- You have already received 2 or 3 previous treatments, including an immunotherapy (PD-1/PD-L1 blocker), and it stopped working.
- You have a measurable tumor that can be seen on a CT scan (not inside the brain).
- You are feeling well enough to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This study tests an experimental drug called IBI363 given before surgery for people with stage II to III non-small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
Hear when a new SCLC,Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.